C-terminal HSP90 inhibitors

1. A pharmaceutical composition comprising a compound of Formula I:

wherein

R 1 is hydrogen, hydroxy, halo, trifluoroalkyl, alkyl, alkenyl, alkynyl, carbocyclic, heterocyclic, aryl, aralkyl, carboxyl, amido, amino, alkoxy, sulfanyl, sulfenyl, sulfonyl, or ether;

R 2 is hydrogen, halo, hydroxy, trifluoromethyl, alkoxy, alkyl, alkenyl, alkynyl, carbocyclic, alkylcarbocyclic, alkylheterocyclic, heterocyclic, or —R 9 —OR 10 , wherein R 9 is a covalent bond or alkyl, and R 10 is hydrogen, alkyl, C-amido or acyl;

R 3 is hydrogen, hydroxy, halo, trifluoroalkyl, alkyl, alkoxy, sulfanyl, or —R 11 —O—R 12 , wherein R 11 is a covalent bond or alkyl, and R 12 is alkyl, C-amido, or acyl;

R 4 is hydrogen or alkyl;

R 5 is hydrogen or alkyl;

R 6 is hydrogen, hydroxy, sulfanyl, alkyl, or alkoxy;

R 7 is hydrogen or hydroxyl;

R 8 is hydrogen or hydroxyl;

X 1 is —CHR 19 —, and wherein R 19 is selected from hydrogen, halo, alkyl, alkenyl, and alkynyl;

X 2 is —CHR 20 —, and wherein R 20 is selected from hydrogen, halo, alkyl, alkenyl, and alkynyl;

X is ═CR 21 — or ═N—, wherein R 21 is hydrogen, halo, trifluoromethyl, alkyl, alkenyl, alkynyl, alkoxy, or hydroxy;

R′ is hydrogen or alkyl;

R″ is alkyl;

Y is ═CR 3 — or ═N—;

Z is CH or Z-Z 1 is —C═C—;

Z 1 is CH or Z-Z 1 is —C═C—; and

n is 0, 1, 2, or 3

and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , wherein X 1 is —CHR 19 —, and wherein R 19 is hydrogen or alkyl; and X 2 is —CHR 20 —, and wherein R 20 is hydrogen or alkyl.

3. The pharmaceutical composition of claim 1 , wherein

R′ is hydrogen,

R″ is CH 3 ,

X 1 is CH 2 , and

X 2 is CH 2 .

4. The pharmaceutical composition of claim 1 , wherein R 4 and R 5 are independently methyl or hydrogen.

5. The pharmaceutical composition of claim 1 , wherein R 6 is selected from hydrogen, hydroxy, methoxy, or alkyl.

6. The pharmaceutical composition of claim 1 , wherein R 7 and R 8 are hydroxy.

7. The pharmaceutical composition of claim 1 , wherein

R 1 is hydrogen, halo, alkoxy, or sulfanyl;

R 2 is hydrogen, hydroxy, halo, trifluoromethyl, or alkoxy;

R 3 is hydrogen, hydroxy, halo, trifluoroalkyl, alkoxy, or sulfanyl;

X is ═CR 21 —, wherein R 21 is hydrogen, halo, or trifluoromethyl; and

Y is ═CR 3 —.

8. The pharmaceutical composition of claim 1 , wherein the compound of Formula I is selected from the group consisting of

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11a);

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3′-fluoro-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11b);

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-4′-fluoro-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11c);

N-(2-(2′-chloro-5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11d);

N-(2-(3′-chloro-5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11e);

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3′-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11f);

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-4′-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11g);

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-2′-(methylthio)-[1,1′-biphenyl]-2-yl)ethyl) acetamide (11h);

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-2′-methoxy-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11i);

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3′-methoxy-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11j);

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3′-methyl-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11k);

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3′-(morpholinomethyl)-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11l);

N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-4′-hydroxy-[1,1′-biphenyl]-2-yl)ethyl)acetamide (11m);

N-(4-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-2-(pyridin-3-yl)phenethyl)acetamide (11o); and

N-(4-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-2-(pyridin-4-yl)phenethyl)acetamide (11p).

9. The pharmaceutical composition of claim 7 , wherein R 1 is hydrogen.

10. The pharmaceutical composition of claim 7 , wherein R 2 is halo.

11. The pharmaceutical composition of claim 10 , wherein R 2 is fluoro.

12. The pharmaceutical composition of claim 7 , wherein R 3 is hydrogen.

13. The pharmaceutical composition of claim 7 , wherein R 21 is hydrogen.

14. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is formulated as a solid.

15. The pharmaceutical composition of claim 14 , wherein the solid is formulated for oral administration.

16. The pharmaceutical composition of claim 14 , wherein the solid is formulated with a therapeutically effective amount of a compound of formula I.